

S Duygu Selcuklu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11658398/publications.pdf>

Version: 2024-02-01

19
papers

3,009
citations

471509

17
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

6506
citing authors

#	ARTICLE	IF	CITATIONS
1	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
2	<i>miR-21</i> as a key regulator of oncogenic processes. <i>Biochemical Society Transactions</i> , 2009, 37, 918-925.	3.4	415
3	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	27.8	361
4	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. <i>Journal of Clinical Oncology</i> , 2016, 34, 2404-2415.	1.6	297
5	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
6	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
7	MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 29516-29528.	3.4	170
8	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
9	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	9.4	138
10	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
11	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	1.6	69
12	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. <i>Cancer Cell</i> , 2021, 39, 1245-1261.e6.	16.8	58
13	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	4.1	37
14	An NTD-Associated Polymorphism in the 3' UTR of MTHFD1L can Affect Disease Risk by Altering miRNA Binding. <i>Human Mutation</i> , 2014, 35, 96-104.	2.5	28
15	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
16	Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 234-239.	2.1	22
17	Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. <i>JCO Precision Oncology</i> , 2021, 5, 44-50.	3.0	20
18	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	3.0	9

#	ARTICLE	IF	CITATIONS
19	Allele-specific splicing effects on DKKL1 and ZNF419 transcripts in HeLa cells. <i>Gene</i> , 2017, 598, 107-112.	2.2	1